<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: : BRAFV600E mutations are associated with poor clinical prognosis in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas selective BRAF inhibitors are effective for treatment of <z:hpo ids='HP_0002861'>melanoma</z:hpo>, comparable efforts in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> have been disappointing </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAFV600E <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We examined <z:chebi fb="0" ids="26025">phosphatidyl</z:chebi> <z:chebi fb="1" ids="24848">inositol</z:chebi> 3-kinase (PI3K)/mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (mTOR) signaling in BRAFV600E <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines after BRAF inhibition and cell viability and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> after combined BRAF and PI3K/mTOR inhibition </plain></SENT>
<SENT sid="4" pm="."><plain>We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAFV600E <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Western blot revealed sustained PI3K/mTOR signaling upon BRAF inhibition </plain></SENT>
<SENT sid="6" pm="."><plain>Our BRAFV600E GEMM presented with sessile serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath>/<z:mpath ids='MPATH_491'>polyps</z:mpath>, as seen in humans </plain></SENT>
<SENT sid="7" pm="."><plain>Combination treatment in vivo resulted in induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0010537'>tumor regression</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We have established a novel GEMM to interrogate BRAFV600E <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> biology and identify more efficacious treatment strategies </plain></SENT>
<SENT sid="9" pm="."><plain>Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials </plain></SENT>
</text></document>